Moffitt Cancer Center and Dyve Biosciences Partner To Advance First-in-Human Studies Targeting Tumor Acidity
TAMPA, Fla. & CAMARILLO, Calif. — Moffitt Cancer Center and Dyve Biosciences today announced a strategic alliance to advance the development of DYV800, a novel topically applied, systemically active therapy that is designed to modulate the local environment of tumors, which suppresses the immune response and promotes treatment resistance. The collaboration will launch a series of clinical studies and translational research efforts to evaluate the safety and biological activity of DYV800 and its potential to enhance outcomes across cutaneous and other solid tumors.
Under the alliance, Moffitt and Dyve will initiate a coordinated research program that includes clinical trials to evaluate the safety and therapeutic potential of DYV800 across various types of cancer. These studies will be supported by laboratory research to identify biomarkers of response to DYV800 and to explore new applications for DYV800, with the goal of gaining a deeper understanding of how modulating the acidity of the tumor environment may enhance treatment response.
The acidity of the tumor microenvironment is known to hinder immune response and reduce the effectiveness of therapies. DYV800, developed by Dyve, provides a topical approach to buffering acidity without disrupting the digestive system, a challenge that limited previous efforts. Early research at Moffitt has shown promising signs of immune activation and improved outcomes in preclinical models, laying the groundwork for further investigation.
“It is well established that the acidity of the tumor environment plays a critical role in suppressing anti-tumor immunity and limiting the effectiveness of cancer treatments,” said John Cleveland, Ph.D., center director and chief scientific officer at Moffitt. “This alliance enables us to accelerate clinical research into modulating the acidity of the tumor microenvironment and to explore its potential in improving outcomes for patients with melanoma and other cancers.”
“Moffitt’s alliance model mirrors institutional scientific diligence and provides access to development-accelerating resources. We’re excited to build upon our multiyear preclinical collaboration and work with more of the world-leading scientists and clinicians at Moffitt to translate the settled science of tumor microenvironment neutralization with DYV800, a patient-friendly topical designed for systemic effect,” said Ryan Beal, MD, CEO of Dyve Biosciences.
About Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 58 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. For more information, call 1-888-MOFFITT (1-844-615-9372), visit MOFFITT.org, and follow the momentum on Facebook, X, Instagram and YouTube.
About Dyve Biosciences
Dyve Biosciences is a clinical-stage company leveraging a proprietary transdermal platform to unlock difficult mechanisms with systemic pharmacology and favorable tolerability. Dyve’s core programs focus on delivering intuitive, targeted pH modulation to treat a range of immunologic and oncologic diseases. For more information, call 1-833-DYVEBIO (1-833-398-3246) and visit DyveBio.com.
###
